Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Cowen & Company's 29th Annual Health Care Conference in Boston on March 16, 2009
Date:3/9/2009

SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Monday, March 16, 2009 at 1:40pm Eastern Time (10:40am Pacific Time) during the Cowen & Company 29th Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston, Massachusetts.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   Anna Gralinska
                Director, Investor Relations
                Cadence Pharmaceuticals, Inc.
                858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
2. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
4. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
7. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
8. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
9. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
10. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
11. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the ... a new blog post about women’s hair loss. Although hair transplant procedures can be ... they age. Menopause or genetics can be two reasons a woman may see her ...
(Date:3/28/2017)... St. Louis, MO (PRWEB) , ... March 28, ... ... high levels of job satisfaction in their profession as their value increases in ... a company that provides resources such as job boards, career fairs, and candidate ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want ... their missing teeth can now have them placed by Dr. Manju Kejriwal, with or ... Cone Beam technology to increase the accuracy of each dental implant placement. The i-CAT ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global flow cytometry ... by 2025, according to a new study by Grand ... and cancer is expected to upsurge the demand for ... coming years. In addition, higher number of physicians is ... cell therapy, due to adverse effects caused by chemotherapy ...
(Date:3/27/2017)... , March 27, 2017 The ... digital health and data analytics company, signed a ... for improving healthcare delivery in the region. ... for Global Health Research and Technology (BIGHEART) at ... on several topics related to healthcare IT and ...
(Date:3/27/2017)... 27, 2017 Therapix Biosciences ... company specializing in the development of cannabinoid-based drugs, today ... the United States of ... 40 ordinary shares of the Company, at a ... has granted the underwriters a 45-day over-allotment option ...
Breaking Medicine Technology: